Hesper Nowatzki
Family · Dubuque, IANPI 1790163848
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$700
- Alkermes, Inc.$555
- Otsuka America Pharmaceutical, Inc.$501
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$480
- Johnson & Johnson$466
- AbbVie$370
- plus $1K from 11 others
What the payments were for
- Food & beverage$4,40597%
- Education$1463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 35 | $700 |
| Alkermes, Inc. | 32 | $555 |
| Otsuka America Pharmaceutical, Inc. | 25 | $501 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $480 |
| Johnson & Johnson | 39 | $466 |
| AbbVie | 21 | $370 |
| Lundbeck LLC | 13 | $300 |
| Neurocrine Biosciences, Inc. | 28 | $288 |
| Vanda Pharmaceuticals Inc. | 8 | $218 |
| Corium, LLC | 11 | $166 |
| Axsome Therapeutics, Inc. | 9 | $158 |
| Indivior Inc. | 8 | $144 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| Almatica Pharma LLC | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Merck | 1 | $18 |
How this compares
$4,551 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 20 | $192,193 |
| IngrezzaValbenazine Tosylate | 19 | $144,646 |
| VraylarCariprazine Hcl | 102 | $138,171 |
| RexultiBrexpiprazole | 71 | $101,642 |
| Invega SustennaPaliperidone Palmitate | 29 | $83,909 |
| TrintellixVortioxetine Hydrobromide | 157 | $80,405 |
| LybalviOlanzapine/Samidorphan Malate | 46 | $74,404 |
| CaplytaLumateperone Tosylate | 43 | $67,217 |
| Wellbutrin XlBupropion Hcl | 24 | $54,709 |
| AristadaAripiprazole Lauroxil | 16 | $48,918 |
| Aripiprazole | 208 | $32,094 |
| Divalproex Sodium ErDivalproex Sodium | 111 | $18,761 |
| Clozapine | 195 | $18,320 |
| Paliperidone ErPaliperidone | 62 | $15,472 |
| BelsomraSuvorexant | 15 | $6,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $466 | $276,10249 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $288 | $144,64619 claims |
| AbbVieVraylar | $370 | $138,171102 claims |
| Alkermes, Inc.Lybalvi, Aristada | $555 | $123,32262 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $501 | $101,64271 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $38 | $80,405157 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $480 | $67,21743 claims |
| MerckBelsomra | $18 | $6,77615 claims |
| Corium, LLCAzstarys | $166 | $4,95112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Dubuque
- Tammi NoonanDubuque$6K
- Janet LabanDubuque$4K
- Kari ErnstDubuque$4K
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.